The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)

British Journal of Pharmacology

Volumn 151, Issue 2, 2007, Pages 163-174

  Hardwick, L J A ^a   Velamakanni, S ^a   Van Veen, H W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ABCG2; ATP binding cassette transporter; Chemosensitizers; Multidrug resistance; Pharmacokinetics; Physiological roles

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; APIGENIN; BENZIMIDAZOLE DERIVATIVE; BIOCHANIN A; BREAST CANCER RESISTANCE PROTEIN; CHRYSIN; DAUNORUBICIN; DIFLOMOTECAN; ELACRIDAR; FLAVOPIRIDOL; FOLIC ACID; FUMITREMORGIN C; GENISTEIN; HESPERETIN; IMATINIB; KAEMPFEROL; KO 132; KO 134; KO 143; METHOTREXATE; MITOXANTRONE; NARINGENIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOVOBIOCIN; OMEPRAZOLE; PANTOPRAZOLE; SILYMARIN; TAG 11; TAG 139; TAMOXIFEN; TOPOTECAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER; CANCER RESISTANCE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; GENOTYPE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ACRIDINES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL; TETRAHYDROISOQUINOLINES; TOPOTECAN;

EID: 34248594839     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707218     Document Type: Review

References (125)

1. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP (2002). Low levels of ABCG2 expression in adult AML blast samples. Blood 100: 4594-4601.
2. Allen JD, Jackson SC, Schinkel AH (2002a). A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res 62: 2294-2299.
3. Allen JD, Van Loevezijn A, Lakhai JM, Van Der Valk M, Van Tellingen O, Reid G et al. (2002b). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1: 417-425.
4. Allikmets R, Gerrand B, Hutchinson A, Dean M (1996). Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet 5: 1649-1655.
5. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337-5339.
6. Bhatia A, Schafer HJ, Hrycyna CA (2005). Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. Biochemistry 44: 10893-10904.
7. Breedveld P, Pluim D, Cipriani G, Wielinga P, Van Tellingen O, Schinkel AH et al. (2005). The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable brain penetration of imatinib in patients. Cancer Res 65: 2577-2582.
8. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH et al. (2004). Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64: 5804-5811.
9. Chen ZS, Robey RW, Belinsky MG, Schvaveleva I, Ren XO, Sugimoto Y et al. (2003). Transport of methotrexate, methotrexate polyglutamines, and 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63: 4048-4054.
10. Clark R, Kerr I, Callaghan R (2006). Multiple drug binding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 149: 506-515.
11. Cooray HC, Blackmore CG, Maskell L, Barrand MA (2002). Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13: 2059-2063.
12. Cooray HC, Janvilisri T, Van Veen HW, Hladky SB, Barrand MA (2004). Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317: 269-275.
13. Cooray HC, Shahi S, Cahn AP, Van Veen HW, Hladky SB, Barrand MA (2006). Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol 531: 25-33.
14. Dalton WS, Cress AE, Alberts DS, Trent JM (1988). Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48: 1882-1888.
15. De Bruin M, Miyake K, Litman T, Robey R, Bates SE (1999). Reversal of resistance by GF120918 in cell lines expressing the ABC halftransporter MXR. Cancer Lett 146: 117-126.
16. Di Pietro A, Conseil G, Pérez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D et al. (2002). Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59: 307-322.
17. Diestra JE, Scheffer GL, Catala II, Maliepaard M, Schnellens JH, Scheper RJ et al. (2002). Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffinembedded material. J Pathol 198: 213-219.
18. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD (1995). Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36: 473-476.
19. Doyle LA, Ross DD, Sridhara R, Fojo AT, Kaufmann SH, Lee EJ et al. (1995). Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulates in leukaemic blast cells. Br J Cancer 71: 52-58.
20. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670.
21. Ebert B, Seidel A, Lampen A (2005). Identification of ABCG2 as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26: 1754-1763.
22. Ee PL, He X, Ross DD, Beck WT (2004a). Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther 3: 1577-1583.
23. Ee PL, Kamalakaran S, Tonetii D, He X, Ross DD, Beck WT (2004b). Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 64: 1247-1251.
24. Ejendal KFK, Diop NK, Schweiger LC, Hrycyna CA (2006). The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci 15: 1597-1607.
25. Faneyte IF, Kristel PM, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JH et al. (2002). Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 8: 1068-1074.
26. Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K et al. (2006). Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 235: 84-92.
27. Fojo T, Bates S (2003). Strategies for reversing drug resistance. Oncogene 22: 7512-7523.
28. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD (2000). Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 18: 2459-2467.
29. Goodell MA, Rosenzweig M, Kim H, Marks DF, Demaria M, Paradis G et al. (1997). Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3: 1337-1345.
30. Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
31. Graf GA, Li WP, Gerard RD, Gelissen I, White A, Cohen JC et al. (2002). Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permit their transport to the apical surface. J Clin Invest 110: 659-669.
32. Han HK, Amidon GL (2000). Targeted prodrug design to optimise drug delivery. AAPS PharmSci 2: E6.
33. Havsteen BH (2002). The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96: 67-202.
34. Higgins CF (1992). ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113.
35. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, Van De Laar A et al. (2001). Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61: 6635-6639.
36. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG (2004). Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. J Biol Chem 279: 25527-25534.
37. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y (2003). Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64: 610-618.
38. Imai Y, Ishikawa E, Asada S, Sugimoto Y (2005). Estrogen-mediated post transcription down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 65: 596-604.
39. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T et al. (2002a). C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1: 611-616.
40. Imai Y, Tsukahara S, Asada S, Sugimoto Y (2004). Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64: 4346-4352.
41. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y (2002b). Estrone and 17-β-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 93: 231-235.
42. Janvilisri T, Shahi S, Venter H, Balakrishnan L, Van Veen HW (2005). Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J 385: 419-426.
43. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, Van Veen HW (2003). Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem 278: 20645-20651.
44. Jin J, Shahi S, Kang HK, Van Veen HW, Fan TP (2006). Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 345: 1308-1314.
45. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ et al. (2002). The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99: 15649-15654.
46. Jonker JW, Merino G, Musters S, Van Herwaarden AE, Bolscher E, Wagenaar E et al. (2005). The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11: 127-129.
47. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JHM et al. (2000). Role of breast cancer resistance protein in the bioavailability of fetal penetration of topotecan. J Natl Cancer Inst 92: 1651-1656.
48. Juliano RL, Ling V (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 445: 152-162.
49. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T et al. (2002). Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 97: 626-630.
50. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T et al. (2001). Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92: 452-458.
51. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M et al. (2002). The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8: 22-28.
52. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J et al. (2005). Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94-101.
53. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D et al. (2004). Functional analysis of SNP variants of BCRP/ABCG2. Pharm Res 21: 1895-1903.
54. Kowalski P, Stein U, Scheffer GL, Lage H (2002). Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 9: 579-586.
55. Kremer JM, Hamilton RA (1995). The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5mg. J Rheumatol 22: 2072-2077.
56. Krishna R, Mayer LD (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265-283.
57. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE et al. (2004). The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279: 24218-24225.
58. Krishnamurthy P, Schuetz JD (2006). Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46: 381-410.
59. Kruijtzer CMF, Beijnen JH, Rosing H, Ten Bokkel Huinink WW, Schot M, Jewell RC et al. (2002). Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and p-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943-2950.
60. Kusuhara H, Sugiyama Y (2006). ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch Eur J Physiol 453: 735-744.
61. Leonard GD, Fojo T, Bates SE (2003). The role of ABC transporters in clinical practice. Oncologist 8: 411-424.
62. Leslie EM, Deeley RG, Cole SPC (2005). Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Tox Appl Pharmacol 204: 216-237.
63. Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, Cole SPC (2001). Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 59: 1171-1180.
64. Li WT, Zhou GY, Song XR, Chi WL, Ren RM, Wang XW (2005). Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference. Neoplasma 52: 219-224.
65. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD et al. (2000). The multidrug-resistant phenotype associated with over-expression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-2021.
66. Litman T, Jensen U, Hansen A, Covitz K, Zhan Z, Fetsch P et al. (2002). Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochim Biophys Acta 1565: 6-16.
67. Lorkowski S, Cullen P (2002). ABCG subfamily of human ATP-binding cassette proteins. Pure Appl Chem 74: 2057-2081.
68. Maliepaard M, Scheffer GL, Faneyte IF, Van Gastelen MA, Pijnenborg ACLM, Schinkel AH et al. (2001). Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61: 3458-3464.
69. Maliepaard M, Van Gastelen MA, De Jong LA, Pluim D, Van Waardenburg RC, Ruevekamp-Helmer MC et al. (1999). Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59: 4559-4563.
70. Mao Q, Unadkat JD (2005). Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7: E118-E133.
71. McDevitt CA, Collins RF, Conway M, Modok S, Storm J, Kerr ID et al. (2006). Purification and 3D structural analysis of oligomeric human multidrug transporters ABCG2. Structure 14: 1623-1632.
72. Merino G, Van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH (2005). Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 67: 1765-1771.
73. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y (2003). Single amino acid substitutions in the transmembrane domain of breast cancer resistance protein (BCRP) alter cross resistance patterns in the transfectants. Int J Cancer 107: 757-767.
74. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Christensen B et al. (1999). Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistance cells: demonstration of homology to ABC transporter genes. Cancer Res 59: 8-13.
75. Mizuarai S, Aozasa N, Kotani H (2004). Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109: 238-246.
76. Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T et al. (2004). Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2- methylamino-4-(3-pyridylmethyl) benzothiasole (E3040) sulphate in breast cancer resistance protein (Bcrp1/Abcg2) knockout mice. Drug Metab Dispos 32: 898-901.
77. Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T (2005). Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett 234: 81-89.
78. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C et al. (1992). Reduced intracellular drug accumulation in the absence of p-glycoprotein (MDR1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52: 6175-6181.
79. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A et al. (2005). Gefitinib ('iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65: 1541-1546.
80. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S et al. (2003a). Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol 64: 1452-1462.
81. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W et al. (2003b). Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 9: 3320-3328.
82. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates SE, Varadi A et al. (2001). Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285: 111-117.
83. Ozvegy C, Varadi A, Sarkadi B (2002). Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. J Biol Chem 277: 47980-47990.
84. Ozvegy-Laczka C, Koblos G, Sarkadi B, Varadi A (2005). Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta 1668: 53-63.
85. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW et al. (2005). Human breast cancer resistance protein (BCRP/ABCG2): interactions with steroid drugs, hormones, the dietary carcinogen PhIP, and transport of cimetidine. J Pharmacol Exp Ther 312: 144-152.
86. Pozza A, Perez-Victoria JM, Sardo A, Ahmed-Belkacem A, Di Pietro A (2006). Purification of breast cancer resistance protein ABCG2 and role of arginine-482. Cell Mol Life Sci 63: 1912-1922.
87. Raaijmakers MHGP, De Grouw EPLM, Heuver LHH, Van Der Reijden BA, Jansen JH, Scheper RJ et al. (2005). Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia. Clin Cancer Res 11: 2436-2444.
88. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T et al. (1998). Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58: 5850-5858.
89. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM (2000). Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60: 47-50.
90. Reid T, Yuen A, Catalico M, Carlson RW (1993). Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 33: 82-84.
91. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T et al. (2001). Overexpression of the ATP-binding cassette half transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7: 145-152.
92. Ross DD, Karp JE, Chen TT, Doyle LA (2000). Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96: 365-368.
93. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG (2001). Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115: 257-262.
94. Sarkadi B, Homoloya L, Szakacs G, Varadi A (2006). Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236.
95. Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F (2002). Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 118: 147-150.
96. Scharenberg CW, Harkey MA, Torok-Storb B (2002). The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99: 507-512.
97. Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S et al. (2006). New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 27: 195-203.
98. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P et al. (2004). Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76: 38-44.
99. Staud F, Pavek P (2005). Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37: 720-725.
100. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A (2002). BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16: 1443-1447.
101. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J et al. (2004). Gefitinib enhances the antitumour activity and oral bioavailability of irinotecan in mice. Cancer Res 64: 7491-7499.
102. Storms RW, Goodell MA, Fisher A, Mulligan RC, Smith C (2000). Hoechst dye efflux reveals a novel CD7+CD34- lymphoid progenitor in human umbilical cord blood. Blood 96: 2125-2133.
103. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T (2003). Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2: 105-112.
104. Sullivan DT, Sullivan MC (1975). Transport defects as the physiological basis for eye color mutants of Drosophila melanogaster. Biochem Genet 13: 603-613.
105. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y (2003). ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278: 22644-22649.
106. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Disc 5: 219-234.
107. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD (2005). Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326: 181-187.
108. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH et al. (1991). Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 63: 923-929.
109. Townsend A, Trowsdale J (1993). The transporters associated with antigen presentation. Semin Cell Biol 4: 53-61.
110. Turner FB, Andreassi JF, Ferguson J, Titus S, Tse A, Taylor SM et al. (1999). Tissue-specific expression of functional isoforms of mouse folylpoly-γ-glutamate synthetase: a basis for targeting folate antimetabolites. Cancer Res 59: 6074-6079.
111. Van Den Heuvel-Eibrink MM, Weimer EA, Prins A, Meijerink JP, Vossebeld PJ, Van Der Holt B et al. (2002). Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16: 833-839.
112. Van Der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, Scheper RJ et al. (2002). Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99: 3763-3770.
113. Van Herwaarden AE, Schinkel AH (2006). The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 27: 10-16.
114. Van Loevezijn A, Van Maarseveen JH, Stegman K, Visser GM, Koomen GJ (1998). Solid phase synthesis of fumitremorgin, verruculogen and tryprostatin analogs based on a cyclization/cleavage strategy. Tetrahedron Lett 39: 4737-4740.
115. Van Veen HW, Margolles A, Muller M, Higgins CF, Konings WN (2000). The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism. EMBO J 19: 2503-2514.
116. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD et al. (2000). Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 60: 3514-3521.
117. Wang H, Zhou L, Gupta A, Vethanayagam RR, Zhang Y, Unadkat JD et al. (2005). Regulation of BCRP/ABCG2 expression by progesterone and 17β-estradiol in human placental BeWo cells. Am J Physiol Endocrinol Metab 290: E798-E807.
118. Xu J, Liu Y, Yang Y, Bates SE, Zhang J (2004). Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 279: 19781-19789.
119. Yanese K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y (2004). Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3: 1119-1125.
120. Yanese K, Tsukahara S, Mitsuhashi J, Sugimoto Y (2005). Functional SNPs of the breast cancer resistance protein; therapeutic effects and inhibitor development. Cancer Lett 234: 73-80.
121. Zhang S, Yang X, Coburn RA, Morris ME (2005). Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 70: 627-639.
122. Zhang S, Yang X, Morris ME (2004). Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65: 1208-1216.
123. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP (2002). Bcrp1 gene expression is required for normal numbers of population stem cells in mice and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99: 12339-12344.
124. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. (2001). The ABC transporter Bcrp1/Abcg2 is expressed in a variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034.
125. Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, Sorrentino BP (2005). Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105: 2571-2576.